No Detail Found!

Outcomes of Autologous Haematopoietic Stem Cell Transplant in Lymphomas: A Single Centre Study

Author(s)
Irsa Hidayat Department of Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Mehreen Ali Khan Department of Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Munazza Nabi Awan Department of Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Awais Siddiq Department of Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Noor Shamim Department of Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Hashim Khan Department of Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
Abstract
To determine the outcomes of autologous haematopoietic stem cell transplant (auto HSCT) in lymphoma patients in terms of overall survival (OS), disease-free survival (DFS), and treatment-related mortality and to identify the associated factors. Study Design: A descriptive study. Place and Duration of the Study: Department of Clinical Haematology, The Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan, from February 2006 to 2023. Methodology: Clinical records of 59 patients who underwent auto HSCT were analysed. Median of OS and DFS was calculated by applying Kaplan-Meier test. Log-rank test was applied to check the association of OS and DFS with multiple variables. In multivariate analysis, Cox-regression was used to check the hazard ratio of signi cant variables. Results: At day 100, the transplant-related mortality of the study was 6.7%, and disease relapse was experienced in 34%. The estimated OS was 82.7% at ve years and 77.6% at 14 years with median OS of 117 months. The estimated DFS was 62% at ve years and 58.6% at 14 years with median DFS of 97 months. Age was the only factor signi cantly associated with both OS and DFS. The subtype of lymphoma, indication to transplant, and septic shock were found signi cantly associated with OS only. While DFS was associated with, time to relapse after rst complete remission (CR). However, at multivariate analysis only septic shock and time to relapse after the rst CR remained signi cant Conclusion: For younger, chemosensitive patients who have experienced their rst CR for a longer duration, auto HSCT is a compelling therapy option in the management of lymphoma.
Publication Details
Page(s) 508-512
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 04, Year: 2025

Request the full text from PASTIC

Keywords
Transplantation, Hodgkin Lymphoma, Autologous, Di use large cell lymphoma
References
Mugnaini EN,Ghosh N.,Lymphoma N. .2016 .. Prim Care, 07(4) : 661-75.
Frietsch JJ,Miethke J,Linke P,Crodel CC,Schnetzke U,Scholl S .2022 .Treosulfan plus udarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell non-hodgkin lymphoma. Bone Marrow Transplantation, 10(7) : 1164-70.
Senapati J,Devasia AJ,Korula A,Fouzia N,Kulkarni U,Lakshmi KM .2022 .Disease status at transplant has a signi cant impact on outcomes of autologous transplantation (ASCT) in patients with hodgkin lymphoma A single center experience. Indian J Hematol Blood Transfus, 10(2) : 290-8.
Burkhardt B,Taj M,Garnier N,Colin VM,Hazar V,Mellgren K .2075 .Treatment and outcome analysis of 639 relapsed non-hodgkin lymphomas in children and adolescents and resulting treatment recommendations. Cancers, 10(9) : .
Dahi PB,Lazarus HM,Sauter CS,Giralt SA .2019 .Strategies to improve outcomes of autologous haematopoietic cell transplant in lymphoma. Bone Marrow Transplant, 10(7) : 943-60.
Faisal MS,Hanel W,Voorhees T,Li R,Huang Y,Khan A .2023 .Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory hodgkin lymphoma in the era of novel agents. Cancer Med, 10(7) : 5631-37.
Lemieux C,Ahmad I,Bambace NM,Bernard L,Cohen S,Delisle JS .2019 .Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for tness and chemosensitive disease. Leuk Res, 01002 : 75-80.
Berro M,Chhabra S,Pinana JL,Arbelbide J,Rivas MM,Basquiera AL .2020 .Predicting mortality after autologous transplant: Development of a novel risk score. Biol Blood Marrow Transplant, 06(10) : 1828-32.
Ali N,Adil SN,Shaikh MU .2015 .Autologous hematopoietic stem cell transplantation-10 years of data from a developing country. Stem Cells Transl Med, 0015(8) : 873-7.
Hajifathali A,Mehdizadeh M,Vosoughi T,Tabarraee M,Talebi A,Sadegh Pezeshki S .2020 .Comparison of survival between hodgkin and non-hodgkin lymphoma after autologous stem cell transplantation. Clin Can Invest J, 112(1) : 19-6.
Brice P,de Kerviler E,Friedberg JW .2021 .Classical Hodgkin lymphoma. Lancet, 6736(20) : 32207-8.
Kadkhoda D,Nikoonezhad M,Baghestani AR,Parkhideh S,Varposhti ZM,Maboudi AAK .2023 .Prognostic factors for the long-term survival after hematopoietic stem cell transplantation in patients with hodgkin lymphoma. Asian Pac J Cancer Prev, 24(2) : 417.
Wudhikarn K,Johnson BM,Inwards DJ,Porrata LF,Micallef IN,Ansell SM .2022 .Outcomes of older adults with nonhodgkin lymphoma undergoing autologous stem cell transplantation: A mayo clinic cohort analysis. Transplant Cellular Ther, 12(3) : e1.
Roerden M,Sökler M,Kanz L,Bethge W,Vogel W,Walz JS .2020 .Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma A long-term follow-up single center experienceA. nn Haematol, 10 : 265-76.
Matin A,Mangaonkar A,Khurana A,Johnston PB,Habermann TM,Ansell S .2019 .Outcomes of adult burkitt lymphoma patients undergoing hematopoietic stem cell transplantation (HSCT) in CR1 versus e CR2-a single institution retrospective analysis. Biol Blood Marrow Transplant, 12(3) : .
Lekakis LJ,Moskowitz CH .2019 .The role of autologous stem cell transplantation in the treatment of di use large B-cell lymphoma in the era of CAR-T cell therapy. doi: 10.1097/HS9, 3(6) : .
Bentolila G,Pavlovsky A .2020 .Relapse or refractory hodgkin lymphoma: Determining risk of relapse or progression after autologous stem-cell transplantationL. euk Lymphoma, 1732959(7) : 1548-54.
Akhtar S,Rauf MS,Elhassan TAM,Khan ZA,Elshenawy MA,Maghfoor I. .2023 .Impact of risk factors and long term survival analysis of patients with primary refractory hodgkin lymphoma who underwent high dose chemotherapy and autologous stem cell transplant. Transplant Cell Ther, 04(7) : 451-2.
Shargian L,Amit O,Bernstine H,Gurion R,Gvili AG,Rozovski U .2023 .The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission A retrospective multicentre study. Eur J Haematol, 10(2) : 149-56.
Hilton LK,Ngu HS,Collinge B,Dreval K,Neriah SB,Rushton CK .2023 .Relapse timing is associated with distinct evolutionary dynamics in di use large B-cell lymphoma. J Clin Oncol, 10(25) : 4164-77.
Goldsmith SR,Ghobadi A,Dipersio JF,Hill B,Shadman M,Jain T. CAR T versus HCT .2022 .An evolving perspective. Transplant Cell Ther, 07(11) : 727-36.
0

Citations

0

Downloads

71

Views